Discover NovoCure's Q1 2025 earnings insights, including Optune Lua's NSCLC progress, global market growth, and strong revenue performance.

Quarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on therapy as of March 31, 2025 Results from Phase 3 PANOVA-3 trial in pancreatic cancer accepted as late-brea ...